3-(piperidin-1-yl)propan-1-ol hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(piperidin-1-yl)propan-1-ol hydrochloride
• 英文别名: 3-piperidino-propan-1-ol; hydrochloride；3-piperidin-1-ium-1-ylpropan-1-ol;chloride
• 化学式: C₈H₁₇NO*ClH
• 分子量: 179.69
• InChiKey: DLJJOWPMZUTLNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.28
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(piperidin-1-yl)propan-1-ol hydrochloride 在 氯化亚砜 、 potassium carbonate 、 potassium iodide 、 lithium hydroxide 作用下， 以 四氢呋喃 、 水 、 丙酮 、 甲苯 为溶剂， 反应 81.0h， 生成 4-(3-(piperidin-1-yl)propoxy)benzoyl chloride hydrochloride
  参考文献：
  名称：

  Bodilisant—A Novel Fluorescent, Highly Affine Histamine H₃ Receptor Ligand

  摘要：

  A piperidine-based lead structure for the human histamine H-3 receptor (hH(3)R) was coupled with the BODIPY fluorophore and resulted in a strong green fluorescent (quantum yield, 0.92) hH(3)R ligand with affinity in the nanomolar concentration range (K-i hH(3)R = 6.51 +/- 3.31 nM), named Bodilisant. Screening for affinities at histamine and dopamine receptor subtypes showed high hH(3)R preference. Bodilisant was used for visualization of hH(3)R in hH(3)R overexpressing HEK-293 cells with fluorescence confocal laser scanning microscopy. In addition, in native human brain tissues, Bodilisant showed clear and displaceable images of labeled hH(3)R.

  DOI：

  10.1021/ml300383n
• 作为产物：
  描述：

  1-哌啶丙醇 在 盐酸 作用下， 生成 3-(piperidin-1-yl)propan-1-ol hydrochloride
  参考文献：
  名称：

  First Metal-Containing Histamine H₃ Receptor Ligands

  摘要：

  Iron-containing ligands targeting the human histamine H-3 receptor (hH(3)R) were prepared. The compounds contain ferrocene sandwich complexes coupled via different linkers to a basic hH(3)R antagonist/inverse agonist pharmacophore. In a click chemistry approach, a triazole was successfully inserted as a new linking element. Two ferrocenylmethylamines and a ferrocenyltriazole were the most affine hH(3)R ligands within this series, showing receptor binding in the nano- and subnanomolar concentration range.

  DOI：

  10.1021/ol100419y

文献信息

• Kojic Acid Derivatives as Histamine H3 Receptor Ligands
  作者：Kerstin Sander、Tim Kottke、Lilia Weizel、Holger Stark

  DOI：10.1248/cpb.58.1353

  日期：——

  surface area (tPSA)) and hence, potentially modifies the pharmacokinetic profile of the different derivatives. Benzyl-1-(4-(3-(piperidin-1-yl)propoxy)phenyl)methanamine ligands 3 and 4 belong to the centrally acting diamine-based class of H(3)R antagonist/inverse agonist, whereas kojic acid analogues 6 and 7 might act peripherally. The latter compounds state promising lead structures in the development

  组胺H（3）受体（H（3）R）是用于治疗主要集中发生的疾病的新化合物的开发中有希望的目标。但是，已经出现了新兴的新型治疗概念，H（3）R领域的某些适应症（例如偏头痛，疼痛或过敏性鼻炎）可能会利用外周作用的配体。在这项工作中，曲酸衍生的结构元​​件被插入到一个完善的H（3）R拮抗剂/反向激动剂支架中，以研究γ-吡喃酮相对于H（3）R药效基团的不同部分的生物等效甾体潜力。最亲和的化合物在低纳摩尔浓度范围内显示受体结合。含曲酸的配体及其相应的苯基类似物（3-7）的评估和比较表明，新整合的支架极大地影响了化学性质（S Log P，拓扑极性表面积（tPSA）），因此可能会改变药代动力学特征不同的衍生品。苄基-1-（4-（3-（3-哌啶基-1-基）丙氧基）苯基）甲胺配体3和4属于H（3）R拮抗剂/反向激动剂的基于中枢作用的二胺类，而曲酸类似物6和7可能在外围起作用。后者的化合物在H（3）R配体的发展过
• Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications
  申请人：——

  公开号：US20040220225A1

  公开（公告）日：2004-11-04

  Use of a compound of formula (A), wherein: 1 W is a residue which imparts antagonistic and/or agonistic activity at histamine H 3 -receptors when attached to an imidazole ring in 4(5) position; R 1 and R 2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H 3 -receptors of histamine.

  使用式(A)的化合物，其中：1W是一个残基，当附加在咪唑环的4(5)位时，赋予组合物在组胺H3受体上的拮抗和/或激动活性；R1和R2可以相同也可以不同，分别独立地表示较低的烷基或环烷基，或者与它们所连接的氮原子一起，表示饱和的含氮环(i)、非芳香性不饱和含氮环(ii)、吗啡环或N-取代哌嗪环，用于制备在组胺H3受体上作为拮抗剂和/或激动剂的药物。
• Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications
  申请人：Schwartz Jean-Charles

  公开号：US20060247223A1

  公开（公告）日：2006-11-02

  Use of a compound of formula (A), wherein: W is a residue which imparts antagonistic and/or agonistic activity at histamine H 3 -receptors when attached to an imidazole ring in 4(5) position; R 1 and R 2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H 3 -receptors of histamine.

  使用公式（A）中的化合物，其中： W是一个残留物，当附加到咪唑环的4（5）位时，赋予组织胺H3受体的拮抗和/或激动活性； R1和R2可以相同也可以不同，并且独立地表示较低的烷基或环烷基，或者与它们附着的氮原子一起，表示饱和的含氮环（i）如定义，非芳香性不饱和含氮环（ii）如定义，吗啉基或N-取代的哌嗪基，如定义，用于制备作为组织胺H3受体的拮抗剂和/或激动剂的药物。
• NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS
  申请人：SCHWARTZ Jean-Charles

  公开号：US20110281844A1

  公开（公告）日：2011-11-17

  Use of a compound of formula (A), wherein: W is a residue which imparts antagonistic and/or agonistic activity at histamine H 3 -receptors when attached to an imidazole ring in 4(5) position; R 1 and R 2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H 3 -receptors of histamine.

  使用公式（A）中的化合物，其中： W是一个残基，当连接到咪唑环的4（5）位置时，赋予组合物在组胺H3受体上的拮抗和/或激动活性；R1和R2可能相同也可能不同，且分别独立地代表较低的烷基或环烷基，或者与它们连接的氮原子一起，代表饱和的含氮环（i），如所定义，非芳香性不饱和含氮环（ii），如所定义，吗啡啶基团，或所定义的N-取代哌嗪基团，以制备在组胺H3受体上作为拮抗剂和/或激动剂的药物。
• 4-substituted octahydroquinolizine analgesic compounds and octahydroquinolizinium intermediates
  申请人：McNeilab, Inc.

  公开号：EP0241292A2

  公开（公告）日：1987-10-14

  Octahydroquinolizine and corresponding octahydroquino­lizinium compounds of formulae (I) and (Va): where A is a 3 to 7 membered carbocyclic ring, R¹ is a substituent, n is 0-2, x is 0-3, and Y is an anion. Also, pharmaceutical compositions for treating pain containing (I) and methods for synthesis and use as well as novel intermediates in the synthesis.

  八氢喹嗪和相应的式 (I) 和 (Va) 的八氢喹嗪鎓化合物： 其中 A 是 3 至 7 个成员的碳环，R¹ 是取代基，n 是 0-2，x 是 0-3，Y 是阴离子。此外，还包括含有(I)的治疗疼痛的药物组合物、合成和使用方法以及合成过程中的新型中间体。